NCATS seeking partners for Gaucher's, heart failure compounds
NIH's National Center for Advancing Translational Science (NCATS) is seeking Cooperative Research and Development Agreement partners to "collaborate in the final stages of lead optimization, in vitro and in vivo evaluation and preclinical development" of two series of compounds. The first comprises small molecule, non-inhibitory chaperones of glucocerebrosidase (GBA; GCase), which are in development with NIH's National Human Genome Research Institute for Gaucher's disease and other disorders such as Parkinson's disease (PD). The second series comprises small molecule agonists of relaxin-insulin-like family peptide receptor 1 ( RXFP1; LGR7) in development for heart failure and fibrosis. According to the Federal Register notices, a statement of interest and capability is due by March 8. ...